-       Report 
- October 2025
-  289 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- August 2025
- Global 
   From       €4383EUR$4,900USD£3,855GBP 
            -       Report 
- October 2025
-  196 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
             -       Report 
- August 2025
-  183 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- January 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- October 2025
-  286 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  377 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  385 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €894EUR$1,000USD£787GBP 
      €1118EUR$1,250USD£983GBP 
          -       Report 
- May 2025
-  120 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
            -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- July 2025
-  198 Pages 
- Global 
   From       €2236EUR$2,500USD£1,967GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- September 2025
-  89 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- March 2025
-  114 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
       
      The Neurological Drug market is composed of drugs used to treat diseases and disorders of the Central Nervous System (CNS). These drugs are used to treat a wide range of conditions, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and stroke. CNS drugs are also used to treat psychiatric disorders, such as depression, anxiety, and schizophrenia. These drugs are typically administered orally, intravenously, or intramuscularly.
The Neurological Drug market is highly    competitive, with many large pharmaceutical companies competing for market share. Companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline are some of the major players in the market. Other companies, such as Eli Lilly, AstraZeneca, and Sanofi, also have a presence in the market. Additionally, there are many smaller companies that specialize in the development and manufacture of CNS drugs. Show Less   Read more